Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

Yale University clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1897
Shown on this page
12
Current sort
Recently updated
Sponsor scope
Yale University
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Yale University. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 61–72 of 1,897 matching trials for sponsor Yale University.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD

NCT04131829
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Fluoxetine - immediate treatment, Fluoxetine - delayed treatment
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Recruiting Phase 1 Interventional

Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study

NCT06335407
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
Interventions
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
Drug
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Recruiting Phase 2 Interventional

Circulating Tumor DNA

NCT06923527
View directory record Official record
Conditions
ER+ Breast Cancer
Interventions
Elacestrant
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Phase 2 Interventional

Janus Kinase Inhibition in Sarcoidosis

NCT05696795
View directory record Official record
Conditions
Sarcoidosis
Interventions
Abrocitinib 200 mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Not applicable Interventional Results available

Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations

NCT05286879
View directory record Official record
Conditions
Opioid Use Disorder, Infectious Disease, Risk Reduction Behavior, Substance Use, Substance Abuse, Stimulant Use Disorder
Interventions
Patient Navigator, Mobile Health Unit
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
New Haven, Connecticut • Dallas, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Recruiting Not applicable Interventional

Music for Pain and Dementia

NCT07602283
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment, Peer-bonded Caregiver, Caregiver
Interventions
Drumming session, Music-listening session
Behavioral
Lead sponsor
Yale University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Phase 3 Interventional

Pharmacological and Behavioral Treatment After Bariatric Surgery

NCT05157698
View directory record Official record
Conditions
Obesity
Interventions
Naltrexone and Bupropion Combination, Behavioral Weight Loss, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Recruiting Not applicable Interventional

Acute Effects of Focused Ultrasound Modulation on EEG Behavior in Status Epilepticus Patients

NCT05784805
View directory record Official record
Conditions
Seizures
Interventions
PLIFU
Device
Lead sponsor
Yale University
Other
Eligibility
19 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Recruiting Not applicable Interventional

A Clinical Trial of Telehealth Treatment for Opioid Use Disorders

NCT07362082
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RecoveryPad platform
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Not applicable Interventional

Mindfulness-Based Ecological Momentary Intervention for Opioid Use Disorder and Chronic Pain

NCT06947122
View directory record Official record
Conditions
Chronic Pain, Opioid Use Disorder
Interventions
Mindfulness based smartphone app
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Completed Not applicable Interventional Results available

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention

NCT04760652
View directory record Official record
Conditions
Depression and Suicide
Interventions
Cognitive Behavioral Therapy CBT, TAU
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • New Haven, Connecticut • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 17, 2026, 7:17 AM EDT
Not yet recruiting Not applicable Interventional

Upper Extremity Vascularized Composite Allotransplantation: A Study Evaluating Safety, Functional Outcomes, and Patient-Reported Psychosocial Outcomes

NCT07810790
View directory record Official record
Conditions
Functional Recovery, Upper Extremity Vascularized Composite Allotransplantation
Interventions
Upper Extremity Vascularized Composite Allotransplantation (VCA)
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2037
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 7:17 AM EDT

About this Yale University sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Yale University is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Yale University trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, trials at Yale in New Haven, CT, or open the full search for Yale University.